Clinical value of diagnosing hepatic fibrosis by Mohamadnejad model and FibroScan in the HBeAg negative chronic hepatitis B virus carriers
10.3760/cma.j.issn.1003-9279.2018.01.015
- VernacularTitle: 利用Mohamadnejad模型和FibroScan诊断HBeAg阴性慢性HBV携带者肝纤维化的临床价值
- Author:
Xiaoying ZHANG
1
;
Jing QIAN
;
Wei HOU
;
Ping LI
;
Yuqiang MI
;
Liang XU
;
Huiqing WANG
Author Information
1. Department of Traditional Chinese and Western Medical Liver Diseases, Tianjin Second People’s Hospital, Tianjin Institute of Hepatology, Tianjin 300192, China
- Publication Type:Journal Article
- Keywords:
Chronic hepatitis B virus carrier;
Noninvasive diagnosis;
Liver biopsy
- From:
Chinese Journal of Experimental and Clinical Virology
2018;32(1):70-74
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical value of diagnosing hepatic fibrosis in the HBeAg negative chronic hepatitis B virus (HBV) carriers by hepatic fibrosis model of Mohamadnejad (M model) and the hepatic instantaneous elastic detector (FibroScan, FS).
Methods:A total of 217 patients were included: they were diagnosed as the HBeAg negative chronic HBV carriers. The value of the hepatic fibrosis was calculated by M model formula, liver stiffness measurements (LSM) was surveyed by FS, and all patients underwent liver biopsy in the same period. According to the degree of hepatic fibrosis in Knodell, one decision point was set: significant hepatic fibrosis (S ≥ 2). The Spearman correlation analysis method was used to analyze the correlation of indicators and the area under receiver operator characteristic curve (AUROC) of M model and FS was drawn.
Results:LSM and M model were positively correlated with the fibrosis stage of liver biopsy (r=0.64, 0.80, P=0.000, 0.000, <0.01). The diagnostic sensitivity, positive likelihood ratio, specificity and negative predictive value of M model and FS for the HBeAg negative chronic HBV carriers with significant hepatic fibrosis were 88.10%, 13.02, 93.23%, 92.50% and 82.14%, 5.20, 84.21%, 88.20%, respectively. The diagnostic AUROC of significant hepatic fibrosis were 0.927 and 0.858, respectively. It had significant statistical difference (Z=2.12, P<0.05).
Conclusions:M model and FS are noninvasive and ideal tools for screening HBeAg negative chronic HBV carriers with significant hepatic fibrosis. The value of diagnosing significant hepatic fibrosis in the HBeAg negative chronic HBV carriers by M model was remarkably higher than that of FS.
